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INTRODUCTION 
Wolfram syndrome (WS) is an autosomal recessive disorder, caused by mutations 
in Wolframin1 (WFS1) gene. WS is characterized by diabetes mellitus, diabetes 
insipidus, optic nerve atrophy, deafness and neural degeneration (Barrett & 
Bundey, 1997; Barrett et al., 1995; Inoue et al., 1998).  
The first symptom to manifest in patients with WS is non-autoimmune 
diabetes, resulting from apoptosis of insulin secreting beta cells (Barrett et al., 
1995; Urano, 2016). Onset of diabetes is dependent of the type of mutation in 
WFS1 gene: earliest onset of diabetes with complete loss of function mutations, 
later onset with partial or minor loss of function mutations (Rohayem et al., 
2011). Diabetes is usually followed by loss of vision due to optic nerve atrophy, 
diabetes insipidus, endocrine and neurological problems (Barrett et al., 1995).  
WS prevalence is estimated between 1 in 770 000 in UK (Barrett et al., 
1995) and 1 in 100 000 in North America (Fraser & Gunn, 1977). However, the 
carrier frequency is approximately 1 in 354 in UK (Barrett et al., 1995) and 1 in 
100–200 in USA (Swift et al., 1991). In addition to rare WFS1 mutations, 
causing autosomal dominant diabetes (Bonnycastle et al., 2013), genome-wide 
association studies (GWAS) have found that the carriers of heterozygous WFS1 
mutation have an increased risk for development of type 2 diabetes (Cheurfa et 
al., 2011; Franks et al., 2008; Han et al., 2010; Sandhu et al., 2007). Type 2 
diabetes mellitus is an expanding health problem all over the world, counting 
for more than 90% of diabetes cases (DeFronzo et al., 2015). Type 2 diabetes is 
caused by combination of lifestyle choices and genetic predisposition, leading 
to decreased insulin sensitivity and secretion (DeFronzo et al., 2015; Olokoba et 
al., 2012). Therefore, deeper knowledge of WFS1 function is useful not only for 
patients suffering from rare WS, but also for patients suffering from more 
common disorders associated with the development type 2 diabetes. For example, 
significant amount of patients suffering from major psychiatric disorders 
(schizophrenia, bipolar disorder and major depressive disorder) develop during 
the course of disease severe insulin resistance and glucose intolerance (Mezuk 
et al., 2008; Vancampfort et al., 2016). Moreover, all these psychiatric disorders 
are associated with the mutations of WFS1 gene (Koido et al., 2005; Swift 
et al., 1998). 
Currently there is no cure or medications to delay the progression of WS, 
therefore treatment is mainly focused on relieving the symptoms (Urano, 2016), 
until death in the third decade of life (Barrett et al., 1995). Therefore, the main 
objectives of the current thesis were to identify new treatment strategies and 
possible drug candidates for the treatment of WS. For the development of 
treatment strategies, both Wfs1 exon 8 knock-out mice and new Wfs1 exon 5 
knock-out rats were used. 
Insulin secretion is modulated by many hormones and neurotransmitters 
including acetylcholine, the major neurotransmitter of the peripheral para-
sympathetic nervous system. Beta cell M3 muscarinic receptors play a key role 
in maintaining proper insulin release and glucose homeostasis (Duttaroy et al., 
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2004; Gautam et al., 2006). Therefore, the first aim of the current thesis was to 
describe the insulin secretion in one of the mouse models of WS and to assess 
the possibility to normalize insulin secretion by the activation of M3 receptors. 
The results confirm the changes in insulin secretion in both homozygous and 
heterozygous Wfs1 mutation carriers. However, pharmacological activation of 
M3 receptors with carbachol is able to activate insulin release from beta cells 
and normalize blood glucose concentration in genetically modified mice. There-
fore, activation of M3 or possibly other GPCR-s that use similar intracellular 
signaling cascades is a promising treatment strategy in diabetes patients with 
WFS1 mutations. 
Unlike human WS patients, none of the current mouse models exhibit overt 
diabetes with basal hyperglycemia (Ishihara et al., 2004; Noormets et al., 2011; 
Riggs et al., 2005), therefore there are some physiological limits in using them 
in drug discovery experiments. In an attempt to generate a model that better 
mimics the development of diabetes in human patients, a new Wfs1 deficient rat 
model was created and validated as a model of WS. In the current thesis, the 
description of development of diabetic phenotype in Wfs1 deficient rats is 
presented. Results show that progressing decrease in Langerhans islet mass, 
most likely due to increased endoplasmic reticulum stress, leads to development 
of insulin dependent diabetes. This is the first rodent model of WS to exhibit 
overt diabetes and clear progression of most of the WS symptoms. 
GLP-1 (glucagon-like peptide-1) receptor agonists have been accepted as a 
promising class of anti-diabetic drugs, shown to regulate glucose homeostasis, 
metabolism, and neural survival directly on tissues expressing GLP-1 receptors, 
and indirectly through neuronal and endocrine pathways (Bockaert & Pin, 1999; 
Persaud, 2017). The GLP-1 agonist Exendin-4 was shown to reduce endo-
plasmic reticulum stress in cardiac myocytes (Younce et al., 2013); early 
intervention with the GLP-1 receptor agonist liraglutide improved glucose 
tolerance and reduced beta cell apoptosis in prediabetic Goto-Kakizaki rats (Luo 
et al., 2013). Also, acute treatment with the GLP-1 agonist exenatide has shown 
a promising anti-diabetic effect in Wfs1 knock-out mice (Sedman et al., 2016). 
After describing a clear evolution of the diabetic phenotype in Wfs1 deficient 
rats, an attempt to prevent the development of diabetes in these rats was taken by 
pharmacological means. For that purpose, treatment with GLP-1 receptor agonist 
liraglutide was started before the onset of first WS symptoms. As described in 
current thesis, 4.5 months of preventive chronic treatment with liraglutide was 
able to preserve normal glucose tolerance and inhibit the loss of Langerhans 
islet mass, by improving the overall islet health and hormone secretion.  
As mentioned above, there is no cure or medications to delay the progression 
of WS (Urano, 2016). In the current study, a GLP-1 analogue displays a clear 
therapeutic effect to prevent or considerably hinder the development of diabetic 
symptoms in Wfs1 deficient rats shown for the first time. We believe that early 
diagnosis of WS and treatment with GLP-1R agonists may prove to also be 
effective in human medicine by significantly improving and prolonging the life 
of WS patients. 
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1. REVIEW OF LITERATURE 
1.1. Blood glucose regulation 
Glucose is used by tissues as the preliminary source of energy. While most 
tissues are also able to use alternative sources of energy (lipids, proteins), with a 
normal diet, neurons rely solely on glucose. Because of that, hypoglycemia can 
result in neuronal death, altered consciousness, coma, and death (Yamada et al., 
2005). While even short-term low blood glucose levels can be life threatening, 
long-term hyperglycemia also causes neurological problems and damages many 
other tissues. To keep blood glucose levels in a specific narrow range, 
hormones and other signaling molecules are constantly at work, to increase or 
decrease blood glucose levels (Guemes et al., 2016). 
Blood glucose is mainly increased by two processes: absorbance of glucose 
from the intestine after a meal and release of glucose stored in the liver. Glucose 
in the liver is stored as polysaccharide glycogen. Between meals, hormone 
glucagon functions as a signaling molecule to release stored glycogen through 
the process of glycogenolysis in response to the lowering of blood glucose 
level. Glucose absorbed during a meal or released from the liver increases blood 
glucose levels, thereby activating insulin secretion from pancreatic beta cells. 
Insulin stimulates glucose pick-up by cells, thereby lowering blood glucose 
levels (Elrick et al., 1956; Vranic et al., 1975).  
 
 
1.2. Insulin secretion 
Langerhans islets of the pancreas are micro-organs, consisting of several 
different cell types. Most important and numerous are glucagon secreting alpha 
cells (up to 20% of islet cells) and insulin secreting beta cells (more than half of 
islet cells) (Elayat et al., 1995). 
Insulin is synthesized in beta cells as precursor protein pre-pro-insulin. Pre-
pro-insulin is cleaved, folded and added three disulfide bonds and then cleaved 
again to form insulin and C-peptide (Patzelt et al., 1978; Huang et al., 1995). 
Insulin and C-peptide are then stored in secretory granules and co-secreted in 
equimolar concentrations (Katz & Rubenstein, 1973). In response to glucose, 
insulin is first secreted in substantial amounts during a short period of time; 
afterwards, lower level of insulin is secreted during a longer second phase 
(Henquin, 2000).  
Glucose is the most important regulator of insulin secretion from pancreatic 
beta cells. For glucose stimulated insulin secretion (GSIS), glucose is trans-
ported into pancreatic beta cells and metabolized, introducing a cascade of events, 
leading to an influx of Ca2+ through voltage operated Ca2+ channels and the 
activation of exocytosis machinery (Henquin, 2000; Milner & Hales, 1967).  
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Insulin secretion can be further potentiated or inhibited by different hor-
mones and neurotransmitters via their effect on cytosolic Ca2+ and cAMP levels 
(Figure 1). This secondary regulation is defective in individuals suffering from 
type 2 diabetes (Del Guerra et al., 2005). 
 
 
Figure 1. Insulin secretion stimulation by Gromada and Hughes, 2006; modified by 
Toots. Ach – acetylcholine; GLP-1 – Glucagon-like peptide-1; GIP – Glucose-dependent 
insulinotropic peptide; IP3 – Inositol trisphosphate; Ca2+ – Calcium ion; PKC – Protein 
kinase C. 
 
First signals to prepare for the increased need for insulin are transmitted through 
para-sympathetic pathways in response to visual and olfactory stimuli. Acetyl-
choline, released from the vagal nerve, binds to muscarinic receptors on the 
surface of beta cells, thereby initiating insulin secretion and amplifying GSIS. 
In small amounts, there are various subtypes of muscarinic receptors present on 
beta cells, but muscarinic 3 receptor (M3R) is shown to be the most prominent 
in the regulation of insulin secretion. Mice lacking M3R have lower serum 
insulin levels and blunted insulin secretion in response to glucose administ-
ration. This effect is also apparent in heterozygous M3R deficient mice, further 
demonstrating the importance of M3R signaling in insulin secretion (Duttaroy 
et al., 2004). 
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Nutrients absorbed in the gut stimulate the release of incretin hormones. 
Incretin hormones are secreted by gut endocrine cells to potentiate insulin 
release after nutrient intake. Most important of these hormones are glucose-
dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1). 
Binding of these hormones to their respective receptors on beta cells amplifies 
GSIS (Parker et al., 2014; Reimann & Gribble, 2016). 
 
 
1.2.1. Glucagon-like peptide-1 
Incretin hormone glucagon-like peptide-1 (GLP-1) is mainly secreted in 
response to meal ingestion by intestinal epithelial endocrine L-cells. In L-cells, 
pro-glucagon is cleaved to glicentin, oxyntomodulin, GLP-1, GLP-2, and inter-
vening peptide 2. GLP-1 affects different cells in manners, still being identified. 
In Langerhans islets, GLP-1 does not only increase insulin and decrease 
glucagon secretion in glucose dependent manner, but also regulates beta cell 
glucose sensitivity, proliferation and apoptosis. Outside pancreas, GLP-1 
increases hepatic glucose disposal and glycogen synthesis by muscles, therefore 
decreasing blood glucose levels (Campbell & Drucker, 2013). 
 
 
1.3. Type 2 diabetes 
Type 2 diabetes (T2D) is the most common form of diabetes mellitus. While 
type 1 diabetes results from autoimmune destruction of insulin secreting beta 
cells, type 2 diabetes develops as a result of the combined effect of lifestyle 
choices and genetic predisposition, leading to decreased insulin sensitivity and 
secretion. The main lifestyle factor in T2D development is obesity, with 
inactivity, alcohol consumption and environmental toxins also having con-
tributing roles (Hu et al., 2001; Wild et al., 2004). In addition to environmental 
factors, there is also a strong genetic component in the development of T2D, as 
having relatives with T2D significantly increases a person’s risk of also 
developing T2D. Genome wide association studies (GWAS) have revealed 
several genes associated with T2D. These genes include for example several 
transcription factors, subunits for voltage gated K-channel, and cation tran-
sporters (Han et al., 2010; McCarthy, 2010). 
Different functions of these genes also reflect the complicated etiology of 
T2D. While T2D is generally characterized with insulin resistance, declining 
insulin secretion, and eventual pancreatic beta cell failure, the severity and 
progression of the disease is very different between patients (Ahlqvist et al., 
2018; Fujioka, 2007). This heterogeneity was recently, to some extent, 
explained by a Swedish research group, identifying five clusters of patients with 
diabetes, which had different patient characteristics and risk of diabetic compli-
cations (Ahlqvist et al., 2018). In their analysis, no genetic loci was associated 
with all clusters, and future GWAS studies might be able to further stratify the 
genetic background in these clusters.  
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Currently there are several different medications used in the treatment of 
T2D, including dipeptidyl peptidase-IV inhibitors, GLP-1 analogues, hypogly-
cemic agents, insulin sensitizers, and glucagon-receptor antagonists (Nathan et 
al., 2009). If T2D truly consists of several types of diabetes with different 
genetic causes, knowing more about the function of implicated genes may help 
to develop new drugs and to assign better drug regime according to patients’ 
specific etiology. 
 
 
1.4. Wolframin protein 
Wolframin1 (WFS1) is a transmembrane protein, mainly located in endo-
plasmic reticulum (ER), but also found in secretory granules in pancreatic beta 
cells (Hatanaka et al., 2011; Philbrook et al., 2005). It has nine transmembrane 
segments and Ncyt/Clum topology (Hofmann et al., 2003). Wolframin is highly 
expressed in different brain tissues, heart, lungs, placenta and pancreas (Inoue et 
al., 1998). In pancreas, Wolframin expression is present in beta cells of Langer-
hans islet, but not in other islet cells or cells outside islets (Ishihara et al., 2004). 
Human WFS1 gene was identified already in 1998 (Strom et al., 1998), but the 
precise function of WFS1 protein is still unknown. So far, most of the research 
indicates WFS1 involvement in ER stress response and ER Ca2+ accumulation 
(Takei et al., 2006; T. Yamada et al., 2006), as Ca2+ concentration in ER 
increases in WFS1 over-expressing cells and is reduced in WFS1 knockdown 
cells (Takei et al., 2006). 
 
 
1.5. Wolfram syndrome 
Defects in WFS1 gene lead to autosomal recessive disorder Wolfram syndrome 
(WS). WS is characterized by diabetes mellitus, diabetes insipidus, optic nerve 
atrophy, deafness and neural degeneration (Barrett & Bundey, 1997; Barrett et 
al., 1995; Inoue et al., 1998). Currently there is no cure to WS and treatment is 
mainly focused on relieving the symptoms (Urano, 2016), until death in the 
third decade of life (Barrett et al., 1995). 
First symptom to manifest in patients with WS at the mean age of six years 
is diabetes mellitus, resulting from progressive beta cell loss (Barrett et al., 
1995). This is most likely due to disruption of intracellular Ca2+ regulation, 
leading to ER stress and apoptosis (Urano, 2016). Diabetes mellitus is usually 
followed at around 11-years-of-age with the loss of color vision and peripheral 
vision due to optic atrophy. Sensorineural deafness, diabetes insipidus, urinary 
tract problems and neurological problems follow, with different frequency and 
severity among patients. WS causes pleomorphic suffering. There are several 
neurological problems associated with WS, including autonomic neuropathy, 
headache, ataxia, dysphagia, and brain stem atrophy. A number of patients 
suffer from psychiatric problems, especially from depression (Swift et al., 
16 
1991). Central apnea due to brain stem atrophy is one of the main causes of 
death in WS patients (Urano, 2016). 
 
 
1.6. WFS1 and type 2 diabetes 
WFS1 is one of the few genes that have been shown to cause monogenic auto-
somal dominant diabetes (Bonnycastle et al., 2013). Even though these domi-
nant WFS1 mutations are rare, genome-wide association studies (GWAS) have 
also shown that the carriers of heterozygous WFS1 mutation have an increased 
risk for development of type 2 diabetes (Cheurfa et al., 2011; Franks et al., 
2008; Han et al., 2010; Sandhu et al., 2007). While WS prevalence is estimated 
to 1 in 770 000 in UK (Barrett et al., 1995) and 1 in 100 000 in North America 
(Fraser & Gunn, 1977), the carrier frequency is approximately 1 in 354 in UK 
(Barrett et al., 1995) and 1 in 100–200 in USA (Swift et al., 1991). The exact 
mechanism involved in this predisposition is not known, but considering WFS1 
role in Ca2+ dynamics, ER stress response, and insulin maturation, heterozygous 
defective WFS1 may lead to beta cell dysfunction (Bonnycastle et al., 2013; 
Urano, 2016). 
 
 
1.7. Previously existing Wfs1 deficient animal models 
There are currently three different mouse models of Wfs1 deficiency, created by 
three separate workgroups. 
Ishihara et al created a full body Wfs1 knock-out by inserting a neomycin-
resistance gene into the second exon of the Wfs1 gene. This resulted in a mouse 
model, where WFS1 function is lost or severely impaired (Ishihara et al., 2004). 
This mouse model shows severe glucose intolerance due to deficit in insulin 
secretion, while insulin tolerance remains unchanged. Isolated islets from these 
mice exhibited increased apoptosis both in response to glucose and inducers of 
ER stress. Compared to wild-type mice, Wfs1 deficient mice insulin content 
was decreased already at two-weeks of age and beta cell mass was decreased at 
two months of age (earliest time-points observed). In [(129Sv×B6)×B6]F2 
hybrid background, these mice started to exhibit increase in basal glucose levels 
in non-fasted state. As this result had very big variance, Wfs1 mutation was 
backcrossed to B6 background, where the increase in basal blood glucose level 
disappeared. Therefore, B6 background probably diminishes the severity of 
symptoms from the lack of functional WFS1 protein. 
Riggs et al created Wfs1 knock-out mice using Cre recombinase under the 
control of insulin promoter and loxP sequences flanking exon 8 of the Wfs1 gene 
(Riggs et al., 2005). This resulted in mice lacking functional WFS1 in pan-
creatic beta cells, but left WFS1 function intact in other tissues. Fasting blood 
glucose levels in most of these mice did not differ from wild-type mice, with the 
exception of a few animals that developed fasting hyperglycemia by 24 months 
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of age. Similarly to mice created by Ishihara et al, beta cell specific knock-out 
of Wfs1 resulted in progressive glucose intolerance, reduced insulin secretion, 
increased apoptosis of beta cells and a decrease in beta cell mass at 24 months 
of age, but not at 12 months of age. 
Luuk et al created whole body Wfs1 knock-out by replacing the majority of 
eighth exon with in-frame NLSLacZNeo cassette (Luuk et al., 2009). This 
resulted in functional WFS1 deficiency, as approximately 60% of total Wfs1 gene 
coding sequence was replaced. Wfs1 deficient mice had lower body weight, and 
similarly to previous models, lower insulin secretion and severe glucose 
intolerance already at two months of age, but did not exhibit significant increase 
in fasted blood glucose levels until a slight increase at 24 months of age (Noor-
mets et al., 2011). 
 
 
1.8. Concluding remarks 
WFS1 protein has a strong impact on the development of diabetes in humans 
with Wolfram syndrome, but also in people carrying one defective copy of the 
gene. WFS1 importance in insulin secretion and beta cell survival is further 
demonstrated by different mouse models, which also develop glucose intolerance. 
However, while human patients with WS develop insulin dependent diabetes at 
an average age of six years, current mouse models seem to not exhibit overt 
diabetes, thus indicating a need for a model, better imitating the progression of 
human condition. 
Beta cell expressed GPCR ligands regulate cell apoptosis, ER stress, Ca2+ 
homeostasis and insulin secretion. All these aspects seem to be affected in Wfs1 
deficiency, therefore, the ligands interacting with GPCR-s on beta cells are 
possible new targets to tackle the problems resulting from defective function of 
WFS1 protein.  
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2. AIMS OF THE STUDY 
The purpose of this study was to create and characterize a new rat model of 
Wolfram syndrome, possibly better mimicking the human condition, and to 
assess the effectiveness of insulin secretion stimulating ligands to reverse and 
prevent insulin secretion deficits in Wfs1 deficient rodent models. 
The specific aims of the study were as follows: 
1.  Describe the insulin secretion in homozygous and heterozygous Wfs1 
deficient mouse model and evaluate muscarinic-receptor agonist carbachol 
ability to normalize insulin secretion in Wfs1 deficient mice. 
2.  Generate a new Wfs1 deficient rat model and characterize the progression of 
diabetes in this model. 
3.  Evaluate the effect of GLP-1 receptor agonist liraglutide to prevent the 
development of glucose intolerance in rat model of WS. 
4.  Evaluate the feasibility of rat model of Wolfram syndrome. 
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3. MATERIALS AND METHODS 
3.1. Animals 
3.1.1. Mice (Paper I) 
The animal experiments described in first study were performed according to 
the permission from the Estonian National Board of Animal Experiments 
(No. 37, 14.08.2014 and No. 55, 14.05.2015) and in accordance with the Euro-
pean Communities Directive of September 2010 (2010/63/EU). Generation of 
Wfs1 exon 8 knockout mice has been described by Luuk et al (Luuk et al., 
2008). In brief, majority of 8th exon of Wfs1 was replaced with in-frame 
NLSLacZNeo cassette, resulting in functional Wolframin1 knock-out. All studies 
were performed in 2 months old male F2 [(129S6/SvEvTac × 129S6/SvEvTac) × 
(129S6/SvEvTac × 129S6/SvEvTac] mice. 2-month-old mice were chosen, as in 
this age, all animals had developed glucose intolerance, but still had enough 
beta cells for the stimulatory effect of carbachol. Average weight of animals 
was 22.9±0.3 grams for WT mice, 23.2±0.3 grams for heterozygous and 
19.2±0.3 grams for homozygous Wfs1-deficient mice. Altogether 180 mice 
were used. Breeding and genotyping were conducted in the Department of 
Biomedicine and Translational Medicine, University of Tartu. Mice were 
housed in groups of seven to eight at 20±2°C under 12/12-h light/dark cycle 
(lights on at 07:00 hours) with free access to standard food pellets and water. 
All animal experiments were carried out between 10:00 and 15:00. Wfs1-
deficient homozygous and heterozygous mice were always used in parallel with 
their WT littermates and the animals were randomly divided between the 
experimental groups (Toots et al., 2018 (1)). 
 
 
3.1.2. Generation of Wfs1 deficient rat line (Paper II) 
Rat Wfs1 exon 5-specific zinc-finger nucleases (ZNFs) and microinjection-ready 
mRNA were obtained from Sigma-Aldrich (CSTZFN-1KT lot: 02091202 MN). 
The Rat Wfs1 exon 5 DNA (deoxyribonucleic acid) sequence and ZFN binding 
and cutting sites are described in Figure 2 (Plaas et al., 2017). 
Figure 2. Zink finger nuclease (ZFN) design and cutting site. Genotyping primers 
are in bold and underlined, ZFN binding site in red, ZFN cut site in lower case red, and 
blue indicates the start and end of exon 5 of the rat Wfs1 gene. Plaas et al., 2017, 
modified by Toots. 
20 
Sprague-Dawley rats (Crl: CD(SD) rats CD® IGS, Charles River Laboratories) 
were housed in standard cages and maintained on a 12 h light/dark cycle with 
ad libitum access to food and water. 4- to 5-week-old embryo donors were 
superovulated by injection with 20 units of pregnant mare serum gonadotropin 
(PMSG Sigma Cat. no. G-4877), and 48 h later, just before mating, rats were 
injected with 50 units of human chorionic gonadotropin (hCG Sigma Cat. no. 
CG-5). Fertilized egg cells were harvested a day later in M2 medium (Sigma 
Cat. No. M7167), and cells where incubated in KSOM medium (Specialty 
Media, Cat. #MR 121-D). For embryo manipulations, ZFN mRNA was injected 
into the pronucleus of fertilized eggs. The final concentration of each ZFN 
mRNA was 2.5 ng/μl. For the synchronization of female recipients, rats were 
injected with 40 μg of LH-Rh 72 h before mating them with vasectomized 
males. Female rats in the proestrus phase were mated with vasectomized studs 
at day 0 to induce pseudo-pregnancy. On the following day (day 1), the mated 
females where inspected for copulatory plugs. Thereafter, microinjected egg 
cells were transferred to the oviduct of pseudopregnant Sprague-Dawley 
recipients (max of 40 embryos per female) (Plaas et al., 2017). 
Mutations in target region were detected using PCR analysis amplify a 333-
bp region surrounding the target site. The resulting PCR products were pyro-
sequenced. The primer set for the PCR genotyping analysis was: rwfs_zf_genoR1 
(5’-AAG AGT GGG TAT GGT GCT GG-3’) and rwfs_zf_genoF1 (5’-AGA 
AGT GGC TAC CCA GGG AT-3’). In the mutation detection assay, we found 
that founder line 232 had 2 bands, indicating a possible large deletion in exon 5 
of the Wfs1 gene. Both of the PCR products were extracted from the agarose gel 
and analyzed via DNA pyrosequencing separately (Plaas et al., 2017). 
To verify the Wfs1 mutation on transcription level, total RNA was extracted 
individually from the hearts of WT and WFS1ex5-KO232 (later marked as 
Wfs1 KO) rats using TRIzol® reagent (Invitrogen, USA) according to the 
manufacturer’s protocol. First-strand cDNA was synthesized using poly(T)18 
oligonucleotides and SuperScript™ III Reverse Transcriptase (Invitrogen, USA). 
Primers for cDNA genotyping and pyrosequencing were as follows: Wfsex4F 
(5’-TCA CTT CTG AGA ATG AGG CCG-3’) and Wfsex7R (5’-ATG AGG 
GCG TTG ATG TGA TGG-3’) (Plaas et al., 2017). 
 
 
3.1.3. Rats (Papers II–III) 
Breeding and genotyping were performed at the Laboratory Animal Centre, 
University of Tartu. For the study of progression of diabetes in rat model of 
WS, 1- to 14-month-old male homozygous Wfs1-deficient and wild-type (WT) 
littermate control rats were used. For the liraglutide study, 2- to 7-month-old 
and 5-month-old male homozygous Wfs1-deficient and WT littermate control 
rats were used. The animals were housed in cages in groups of 2–4 animals per 
cage under a 12 h light/dark cycle (lights on at 7 a.m.). Rats had unlimited 
access to food and water except during testing. Sniff universal mouse and rat 
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maintenance diet (Sniff #V1534) and reverse osmosis-purified water were used. 
Experiments were performed between 9 a.m. and 5 p.m. Permission for this 
study was given by the Estonian National Board of Animal Experiments (No. 
54, 23th of February 2015 and No 103, 22nd of May 2017) in accordance with 
the European Communities Directive of September 2010 (2010/63/EU) (Plaas 
et al., 2017; Toots et al., 2018 (2)). 
 
 
3.2. Animal experiments 
3.2.1. Intraperitoneal glucose tolerance test (IPGTT) in mice (Paper I) 
For IPGTT, food was removed 90 min prior to the beginning of experiment. 
90 min fasting was used, as it was sufficient to allow blood glucose levels to 
equalize while having smaller effect on metabolic parameters, observed with 
longer fasting (Agouni et al., 2010; Andrikopoulos et al., 2008; Palou et al., 
2008). Basal levels of blood glucose were determined from the tail vein by 
needle puncture, using commercial glucose meter (Accu-Check Performa, 
Roche). After that, mice were given i.p. injection according to their body weight 
with a) 2 g/kg glucose; b) 0.02 mg/kg carbachol (carbamoylcholine chloride, 
muscarinic receptor agonist); or c) 2 g/kg glucose + 0.02 mg/kg carbachol. 5, 10 
or 30 minutes later animals were euthanized, blood samples collected for insulin 
measurement and blood glucose levels determined. Carbachol (SigmaAldrich) 
and D-(+)-glucose (SigmaAldrich) were both dissolved in saline (0,9% NaCl; 
B. Braun). Carbachol concentration 0.02 mg/kg was chosen as it corresponds to 
1 µmol/kg dose and approximately 10 µM concentration in blood, showing 
strong effects in previously reported experiments (Gautam et al., 2007; Johnson 
et al., 2005; Renuka et al., 2006; Toots et al., 2018 (1)). 
 
 
3.2.2. Intraperitoneal glucose tolerance test (IPGTT) in rats  
(Papers II–III) 
Animals were deprived of food for 3 h before and during the experiment; water 
was available throughout the experiment. D-Glucose (Sigma-Aldrich) was dis-
solved in 0.9% saline solution (20% w/vol) and administered intraperitoneally 
at a dose of 2 g/kg of body weight. Blood glucose levels were measured at the 
indicated time points from the tail vein using a handheld glucometer (Accu-
Check Go, Roche, Germany). Blood samples were drawn from the tail vein 
immediately before and 30 min after glucose administration for further analyses 
(Plaas et al., 2017; Toots et al., 2018 (2)).  
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3.2.3. Subcutaneous insulin tolerance test (ITT) (Papers II–III) 
An insulin tolerance test was performed in the same manner as the glucose 
tolerance tests except that human insulin (1 unit/kg s.c., Lantus Solostar) was 
administered instead of glucose (Plaas et al., 2017; Toots et al., 2018 (2)). 
 
 
3.2.4. 8-day repeated liraglutide treatment (Paper III) 
In this experiment, 5-month-old rats were used. After the first IPGTT test, the 
rats received 0.4 mg/kg liraglutide (Novo Nordisk, Denmark, solution made in 
0.9% NaCl) subcutaneously for 8 days. Injections of 1 ml/kg volume were 
administered once a day between 8 and 11 a.m. The second IPGTT was per-
formed 4.5 hours after the last liraglutide injection (Toots et al., 2018 (2)). 
 
 
3.2.5. Chronic liraglutide treatment (Paper III) 
The rats were 2 months old at the beginning of the experiment. After the first 
IPGTT test, the rats were randomly allocated into the liraglutide or control 
group. The liraglutide group animals received 0.4 mg/kg liraglutide (Novo 
Nordisk, Denmark) and the control group animals a 0.9% saline solution 
(vehicle) subcutaneously. Injections of 1 ml/kg volume were made once a day 
between 8 and 11 a.m. (or immediately after a glucose/insulin tolerance test). 
Rats were weighed once a week. Glucose tolerance and insulin tolerance tests 
were performed 24 hours after the previous liraglutide/saline injection. After the 
last IPGTT, rats were equally allocated for subsequent histological/quantitative 
real-time PCR analysis according to their IPGTT results (Toots et al., 2018 (2)). 
 
 
3.3. Biochemical and gene expression analyses 
3.3.1. Urine glucose concentration measurements (Paper II) 
Urine from non-fasted rats was collected during the light phase for urine glucose 
levels measurement and determined using standardized procedures at the United 
Laboratories of Tartu University Hospital (Plaas et al., 2017). 
 
 
3.3.2. Insulin, C-peptide, and Glucagon measurements (Papers I–III) 
For serum separation, blood was allowed to clot, centrifuged for 15 min at 
2000x g, and stored in –80 oC until further analysis. Serum insulin levels were 
measured using an ultra-sensitive mouse insulin ELISA kit (CrystalChem 
cat#90080) or, an ultra-sensitive rat insulin ELISA kit (CrystalChem cat# 
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90060), C-peptide levels were measured using rat C-peptide ELISA 
(CrystalChem cat# 90055), and glucagon levels were measured using rat 
glucagon ELISA (CrystalChem cat# 81519), according to the manufacturer’s 
instructions (Plaas et al., 2017; Toots et al., 2018 (1); Toots et al., 2018 (2)).  
 
 
3.3.3. Gene expression analyses from Langerhans islets (Papers II–III) 
3.3.3.1. Langerhans islet isolation 
Islets of Langerhans were isolated as has been described previously (Carter et al., 
2009). In brief, 0.9 mg/ml collagenase (Sigma-Aldrich, #C7657) solution was 
injected into the common bile duct of euthanized animals; inflated pancreases 
were collected and tissues enzymatically dispersed. The majority of exocrine 
tissue was removed by gradient separation in Histopaque solution (Sigma-
Aldrich). Islets of Langerhans were collected by hand from remaining exocrine 
tissue under a stereo microscope (Plaas et al., 2017; Toots et al., 2018 (2)).  
 
 
3.3.3.2. RNA extraction and cDNA synthesis 
RNA from islets of Langerhans was isolated using Direct-zol RNA MiniPrep 
(Zymo Research), according to the manufacturer’s protocol. First-strand cDNA 
was synthesized using random hexamers and SuperScript™ III Reverse 
Transcriptase (Invitrogen, USA) (Plaas et al., 2017; Toots et al., 2018 (2)). 
 
 
3.3.3.3. Xbp1 splicing 
Xbp1 splicing was analyzed using rat Xbp1-specific PCR as has been described 
(Yusta et al., 2006). In brief, PCR was performed with primers 5’-AAA CAG 
AGT AGC AGC ACA GAC TGC-3’ and 5’-TCC TTC TGG GTA GAC CTC 
TGG GAG-3’. The program for amplification was: 15 min 95 oC; 30 × (20 sec 
95 oC; 45 sec 60 oC; 60 sec 72 oC); 10 min 72 oC. PCR products were separated 
on 3% agarose gel for approximately 5.5 hours, 145 mV, and images obtained 
using Uvidoc imaging system. Integrated density levels were measured using 
ImageJ software. Xbp1 spliced from the whole Xbp1 was calculated and nor-
malized to their expression in WT (Paper II) or WT saline-treated (Paper III) 
rats (Plaas et al., 2017; Toots et al., 2018 (2)). 
 
 
3.3.3.4. Quantitative real-time PCR 
Gene expression was analyzed using quantitative real-time PCR (qRT-PCR) 
with TaqMan Gene Expression Assays (Table 1; Thermo Fisher Scientific), and 
Taqman Gene Expression Mastermix (Thermo Fisher Scientific). Wfs1 assay 
binds to exon 1 and 2 boundary, therefore also recognizes mutant Wfs1 lacking 
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exon 5. Relative quantification was performed using the 2–∆Ct method, with 
Hprt1 (has been shown to have stable expression levels) as an internal control. 
All gene expressions were done in three parallels to minimize possible errors 
and results were normalized to their expression in WT (Paper II) or WT saline-
treated (Paper III) rats (Plaas et al., 2017; Toots et al., 2018 (2)). 
 
Table 1. Taqman assays used 
Gene symbol Paper Assay ID 
Grp78 (Bip) II, III Rn00565250_m1 
Glp1R III Rn00562406_m1 
Wfs1 III Rn00582735_m1 
Atf4 III Rn00824644_g1 
Bax III Rn01480161_g1 
Caspase1 III Rn01515235_m1 
Caspase3 III Rn00563902_m1 
Bcl2 III Rn99999125_m1 
IP10 III Rn01413889_g1 
Ki67 III Rn01451446_m1 
Hprt1 II, III Rn01527840_m1 
Grp78 (Bip) – 78 kDa glucose-regulated protein; Glp1R – Glucagon-like protein-1 
receptor; Wfs1 – Wolframin1; Atf4 – activating transcription factor 4; Bax – Bcl-2-
associated X protein; IP10 – interferon gamma-induced protein 10; Ki67 – antigen  
KI-67; Hprt1 – hypoxanthine-guanine phosphoribosyltransferase 
 
 
3.4. Immunohistochemistry (Paper II) 
Rats were anaesthetized with an intraperitoneal injection of ketamine (100 mg/kg) 
and dexmedetomidine (500 µg/kg) and were then perfused transcardially with 
4% paraformaldehyde (PFA, Sigma-Aldrich) in 0.1 M phosphate buffer (PB, 
pH 7.4). Pancreases were dissected and further fixed in the same fixative over-
night at 4 °C. Tissues were cryoprotected in 30% sucrose (AppliChem)/0.1 M PB 
solution until they sank and were then frozen at –80 °C until further use. 
Sections (40 µm thick) were cut using a cryomicrotome (Microm HM-560) and 
collected on Superfrost Polysine Slides (Thermo Scientific). After washing with 
phosphate buffered saline (PBS) for 10 min, sections were permeabilized with 
0.2% Triton X-100 (Naxo, Tartu, Estonia)/PBS solution for 40 min. Sections 
were further incubated in a blocking solution containing 5% donkey serum/1% 
bovine serum albumin (BSA, Sigma-Aldrich)/PBS for 2 h at room temperature. 
Primary and secondary antibodies were diluted in 0.1% Tween-20/1% BSA/ 
PBS. Sections were incubated with primary antibodies for 12 h at 4 °C and were 
then washed with PBS for 1 h. Sections were incubated with the appropriate 
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secondary antibody at room temperature for 2 h. After subsequent washes with 
PBS (1 h), cell nuclei were counterstained with DAPI (4’,6-diamidino-2-
phenylindole, Sigma-Aldrich) at a 1:2000 dilution in 0.1% Tween-20/PBS for 
15 min and further washed with PBS. Sections were mounted in Vectashield 
mounting medium (Vector Laboratories Inc.) and covered with a 0.17-mm 
coverslip (Deltalab). Images were taken with an Olympus FV-1000 (Olympus) 
confocal microscope or Olympus BX51 Fluorescence Microscope and 
annotated with Adobe Photoshop CC (Adobe Systems Incorporated) (Plaas et 
al., 2017). 
Primary antibodies and their dilutions were as follows: rabbit anti-XPB1 
(1:500, Abcam Cat# ab 37151, RRID:AB_778942), rabbit anti-BiP (1:200, Cell 
Signalling Technology Cat# 3177P, RRID:AB_10828008). Secondary antibody 
dilution was: FITC AffiniPure donkey anti-rabbit (1:1000, Jackson 
ImmunoResearch Lab., 711-095-152, RRID:AB_2315776) (Plaas et al., 2017). 
Histological analyses were performed using material from 3 to 7 animals per 
genotype from each age group. Negative controls were made without primary 
antibody. Representative images for each group are shown. Fluorescence 
intensity measurements of ER stress markers were performed using ImageJ 
software (NIH, Bethesda, MD, USA). Specifically, 8-bit images from optical 
sections approximately 5 µm thick were converted to greyscale, and intensity 
values were measured as the mean pixel value in the islets of Langerhans (Plaas 
et al., 2017). 
 
 
3.5. Langerhans islet measurements (Papers II–III) 
Beta cell mass was estimated as has been described previously (Iglesias et al., 
2012). In brief, rats were perfused, their pancreases dissected, and excess fat 
removed. The weight of each pancreas was recorded, and the tissue was 
processed for histological analysis as described earlier. 40-μm-thick sections 
were cut at intervals of 400 μm (Plaas et al., 2017; Toots et al., 2018 (2)). 
Sections were washed with PBS for 3x5 min, permeabilized with 0.2% 
Triton X-100 (Naxo, Estonia)/PBS solution for 30 min, incubated in 0.5% 
H2O2/PBS for 1 h, and blocked in 5% donkey serum/1% bovine serum albumin 
(BSA, Sigma-Aldrich)/PBS for 1 h. Primary and secondary antibodies were 
diluted in 0.1% Tween-20/1% BSA/PBS. Sections were incubated with mouse 
anti-insulin antibody (1:800, Cell Signaling Technology Cat# 8138S 
RRID:AB_10949314) for 1 h and washed with PBS for 3x10 min, followed by 
incubation with donkey anti-mouse peroxidase conjugated antibody (1:2000, 
Rockland Cat# 610-703-002 RRID:AB_219700) for 30 min and washed with 
PBS 3x5 min. Sections were incubated in 0.025% diaminobenzidine (Sigma 
Aldrich)/0.005% H2O2/0.05% CoCl2 (Sigma Aldrich)/PBS for 15 min and 
washed with water. Dried sections were mounted using PeRtEx (HistoLab) and 
covered with 0.17 mm coverslip (Deltalab). Images were taken using a Leica 
SCN 400 slide scanner at 20x magnification. The images obtained were 
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analyzed using the ImageJ software. Langerhans islet mass for each animal was 
estimated by dividing the total islet area by the total pancreas area, and the 
obtained relative islet area was multiplied by the weight of the pancreas to 
estimate Langerhans islet mass (Plaas et al., 2017; Toots et al., 2018 (2)).  
 
 
3.6. Statistical analysis (Papers I–III) 
The data are presented as the mean ± SEM and were compared using factorial 
or repeated measures ANOVA (after positive Shapiro-Wilks normality test) 
followed by unequal N HSD post hoc tests. The data were analyzed using 
version 8 of the Statistica software (Statistica, USA). p<0.05 was considered 
statistically significant. 
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4. RESULTS AND DISCUSSION 
4.1. Insulin secretion in Wfs1 deficient mice (Paper I) 
4.1.1. Early response insulin secretion in Wfs1 deficient mice 
Prior to meal consumption, neuroendocrine signals prepare beta cells for the 
increased need for insulin secretion. Acetylcholine released by vagus nerve 
binds to muscarinic receptors on beta cells to release insulin and to amplify GSIS. 
Muscarinic agonists have been previously shown to initiate insulin secretion in 
diabetic models, an effect that is abolished by muscarinic antagonist atropine 
(Ahren et al., 1997; Guenifi et al., 2001). None of these agonists are specific to 
one muscarinic or nicotinic receptor subtype. However, studies investigating 
acetylcholine effect on pancreatic beta cells and insulin secretion have revealed 
the central role of M3R (muscarinic receptor 3), as M3R deficient mice do not 
exhibit increased glucose stimulated insulin secretion after treatment with 
muscarinic agonist oxotremorine (Duttaroy et al., 2004). It should be taken into 
account that a small proportion of the activity of muscarinic agonists may be 
related to other muscarinic receptor subtypes and even to nicotine receptors, but 
the direct effect and even expression of other receptors than M3 is still debated 
upon (Duttaroy et al., 2004; Toots et al., 2018 (1); Yoshikawa et al., 2005). 
While previous reports have described lower insulin levels in Wfs1 KO 
mice, we aimed to further study the changes in insulin secretion dynamics in 
Wfs1 deficient mice (Noormets et al., 2011). For this, WT, Wfs1 mutation 
heterozygous, and Wfs1 mutation homozygous mice were injected with 2 g/kg 
glucose and blood samples were collected at different time-points. 
Similarly to previous reports (Noormets et al., 2011), our findings confirmed 
the significant impairment in glucose stimulated insulin secretion in Wfs1 
deficient mice (Figure 3). Glucose injection caused strong hyperglycemia in 
Wfs1 KO mice, explained by the lack of insulin secretion in response to glucose. 
Heterozygous mice blood glucose levels did not differ from that of WT mice, 
but their insulin levels stayed elevated for longer, indicating changes in insulin 
secretion dynamics. This coincides with heterozygous WFS1 mutation carriers 
having increased risk for the development of type 2 diabetes, most likely due to 
changes in beta cell function, represented by altered insulin secretion (Cheurfa 
et al., 2011; Franks et al., 2008; Han et al., 2010; Sandhu et al., 2007; Toots et 
al., 2018 (1)). 
To further study the changes in early insulin secretion and possible changes 
in response to muscarinic stimulation, mice were administrated 0.02 mg/kg 
carbachol. Carbachol activates muscarinic receptors present on the surface of 
beta cells (Duttaroy et al., 2004). 
While carbachol did not change the blood glucose levels compared to 
baseline measurements, it had a significant effect on insulin release (Figure 4). 
In WT mice, there was a five-time increase in insulin secretion during 5 to 10 
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minutes after injection. In both homozygous and heterozygous Wfs1 deficient 
mice, this early response of insulin secretion was approximately half of that 
seen in WT mice. This experiment further revealed the changes in heterozygous 
mice insulin secretion, first observed during GSIS. Regulation of insulin secretion 
by hormones and/or neurotransmitters (e.g. acetylcholine effect through M3 
receptors on beta cell) is defective in people with type 2 diabetes (Del Guerra et 
al., 2005). Human GWAS studies have revealed that heterozygous Wfs1 
mutation carriers have increased risk for development of type 2 diabetes 
(Cheurfa et al., 2011; Franks et al., 2008; Han et al., 2010; Sandhu et al., 2007). 
This correlates with experiments on Wfs1 deficient mice, where psychiatric 
drugs amitriptyline and desipramine, that block M3 receptor as a side-effect, 
caused stronger increase of blood glucose levels in Wfs1 heterozygous mice 
than in WT mice and hyperglycemia in Wfs1 homozygous mice (Reimets et al., 
2016; Toots et al., 2018 (1)).  
 
Figure 3. Response to 2 g/kg glucose injection. Blood glucose (a) levels 5, 10 or 
30 minutes after administration and corresponding area under curve (b). Serum insulin 
(c) levels 5, 10 or 30 minutes after administration and corresponding area under curve 
(d). *** p < 0.001 compared to baseline level of same genotype. # p < 0.05, ## p < 0.01, 
### p < 0.001 compared to WT in same time-point. WT – wild-type mice; HET – 
heterozygous Wfs1 mutation carrier; KO – homozygous Wfs1 mutation carrier. n=5–7. 
Toots et al., 2018 (1), modified by Toots. 
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Figure 4. Response to 0.02 mg/kg carbachol injection. Blood glucose (a) levels 5, 10 
or 30 minutes after administration and corresponding area under curve (b). Serum 
insulin (c) levels 5, 10 or 30 minutes after administration and corresponding area under 
curve (d). * p < 0.05, *** p < 0.001 compared to base level of same genotype.  
# p < 0.05, ## p < 0.01, ### p< 0.001 compared to WT in same time-point. WT – wild-
type mice; HET – heterozygous Wfs1 mutation carrier; KO – homozygous Wfs1 
mutation carrier. n=5–7. Toots et al., 2018 (1), modified by Toots. 
 
 
4.1.2. Carbachol and glucose co-administration to Wfs1 deficient mice 
As carbachol administration was able to release insulin from homozygous Wfs1 
deficient mice beta cells, we further investigated whether co-administration of 
carbachol with glucose is able to prevent hyperglycemia in KO mice. 
Co-administration of carbachol and glucose increased blood glucose levels 
in all genotypes (Figure 5a). The blood glucose level in KO animals was 
somewhat higher at the time-point 10 minutes compared to other genotypes, but 
long-lasting hyperglycemia that existed in KO mice administrated only glucose, 
had normalized after 30 minutes (Figure 3a and 5a) (Toots et al., 2018 (1)).  
Furthermore, co-administrated KO mice blood glucose profile was similar to 
WT mice receiving glucose (Figure 6a). This normalization of glycemic control 
was explained by the fact that even though early response serum insulin levels 
in co-injected WT and HET mice were significantly higher than in KO mice 
(Figure 5c), KO mice were able to secrete insulin in levels similar to WT mice 
receiving only glucose (Figure 6b) (Toots et al., 2018 (1)). 
  

	



	


	

	

	









  




! 






"
#$


%

' (
  



 
	

	

	



 







 

  

	
	
&	



	 





"
#$

 
%


 
30 
Figure 5. Response to 0.02 mg/kg carbachol and 2 g/kg glucose co-injection. Blood 
glucose (a) levels 5, 10 or 30 minutes after administration and corresponding area under 
curve (b). Serum insulin (c) levels 5, 10 or 30 minutes after administration and 
corresponding area under curve (d). *** p < 0.001 compared to baseline level of same 
genotype. ### p < 0.001 compared to WT in same time-point. WT – wild-type mice; 
HET – heterozygous Wfs1 mutation carrier; KO – homozygous Wfs1 mutation carrier. 
n=5–7. Toots et al., 2018 (1), modified by Toots. 
 
 
Figure 6. WT and KO mice 
response to 2 g/kg glucose 
or 0.02 mg/kg carbachol 
and 2 g/kg glucose  
co-injection. Blood glucose 
(a) and insulin (b) area 
under curve during 30 
minutes after injection. 
WT – wild-type mice;  
KO – homozygous Wfs1 
mutation carrier. n=5–6. 
Toots et al., 2018 (1), 
modified by Toots.  
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4.1.3. Conclusion 
Wfs1 deficiency causes glucose intolerance as a result of decreased insulin 
secretion. This deficit is also apparent in heterozygous Wfs1 deficient mice who 
do not exhibit glucose intolerance. These changes in heterozygous mice may 
explain the increased risk for development of type 2 diabetes in human WFS1 
mutation carriers. Activation of M3 receptors on beta cell by carbachol was able 
to initiate insulin secretion from beta cells and normalize blood glucose control 
in Wfs1 deficient mice. 
Carbachol inability to distinguish between M3R and other types of mus-
carinic/nicotinic receptors limits its use in human diabetes treatment. However, 
selective M3R agonists and possibly other ligands, able to activate same 
pathways in beta cell, are a promising way to release insulin and to reverse 
glucose intolerance resulting from Wfs1 deficiency (Toots et al., 2018 (1)). 
 
 
4.2. Generation and characterization of new Wfs1  
deficient rat model (Paper II) 
4.2.1. Generation of rat line without exon 5 of Wfs1 gene 
While human patients of WS develop insulin dependent diabetes at a young age 
(average age 6 years), none of the three mouse models of WS created to this 
date, exhibit consistently developing overt diabetes (Ishihara et al., 2004; Noor-
mets et al., 2011; Riggs et al., 2005; Urano, 2016). In hopes of creating a model 
better mimicking the human condition diabetes and other symptoms of WS, as 
well as to make live imaging of neural degeneration more precise, a rat model 
of Wfs1 deficiency was created. 
Using zinc-finger technology, three different Wfs1 mutant rat lines were 
created. Genomic sequencing revealed that two of the lines (Wfs1-ex5-KO232 
and Wfs1-ex5-KO266) had an in frame deletion in exon 5 of the Wfs1 gene and 
the third line (Wfs1-ex5-INS244) had an in frame substitution in exon 5 of the 
Wfs1 gene. This substitution is predicted to result in amino-acids 224–226 (LQK) 
being substituted with YCMNTI in the WFS1 protein (Plaas et al., 2017). 
Rats from all three lines exhibited glucose intolerance at 7 months of age 
(Figure 7a-c), further demonstrating that glucose intolerance effect was most 
likely not an off-target effect. Both of the strains with deletion in Wfs1 gene 
exhibited lower body mass compared to WT littermates at 7 months of age, 
while the Wfs1 mutation line with insertion exhibited higher body mass, 
compared to WT littermates (Figure 7d-f). Mutation of Wfs1 in Wfs1-ex5-
KO232 rats was verified by pyrosequencing cDNA, which confirmed a deletion 
of exon 5 of the rat Wfs1 gene (Figure 8a). This deletion is predicted to result in 
a loss of 27 aa from the WFS1 protein sequence (aa 212-238) and a substitution 
of serine to alanine at position 239 (Figure 8b) in Wfs1-ex5-KO232 rats. The 
32 
Wfs1-ex5-KO232 line (in further studies Wfs1 KO or KO) was characterized 
and used (males only) in the subsequent experiments, but all 3 Wfs1 mutant 
lines are currently being maintained for future studies (Plaas et al., 2017). 
Figure 7. Glucose tolerance and body weight of three different Wfs1 mutant rat-lines 
at 7 months of age (males). (a, b, c) All Wfs1 mutant rats display glucose intolerance at 
this age. (d, e) Wfs1-ex5-KO232 and Wfs1-ex5-KO266 rats are lighter than wild-type 
littermates. (f) Wfs1-ex5-INS244 rats are heavier than littermates. Student’s t-test; *p < 
0.05, ** < 0.01 between genotypes. The data are presented as mean ± SEM, n=4 –7. 
Plaas et al., 2017, modified by Toots. 
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33 
Figure 8. Wfs1-ex5-KO232 mutation in rats. (a) DNA Sequence of exon 5 of the 
Wfs1 deficient rat line 232. Rat line Wfs1-ex5-KO232 lost 184 bp (17,833 – 18,017) in 
the Wfs1 gene, including 55 bp in exon 5; blue indicates the start and end of exon 5. (b) 
Comparison of cDNA and protein sequences from wild-type (WT) and Wfs1-ex5-
KO232 rat lines. Line Wfs1-ex5-KO232 has lost all nucleotides from coding exon 5 of 
the Wfs1 gene. According to cDNA sequencing and ORF analysis, the resulting strain 
had lost exon 5 in the Wfs1 gene. Protein sequence is predicted from cDNA analysis; 
deletion of 55 bp from exon 5 of the rat Wfs1 gene did not result in a frame-shift 
mutation. Thus, there is a loss of 27 amino acids (from coding exon 5 of the Wfs1 gene) 
and a new GCC codon (coding A – alanine) at the junction of exon 4 and exon 6 in the 
Wfs1-ex5-KO232 rats (marked red). Plaas et al., 2017, modified by Toots. 
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4.2.2. Development of diabetes in Wfs1 KO rats 
4.2.2.1. Glucose tolerance, insulin secretion and insulin sensitivity 
To characterize the development of glucose intolerance and diabetes in Wfs1 KO 
rats, we assessed their response to glucose challenge at different ages. Results 
revealed that similarly to human patients who do not develop diabetes until 
around 6-years-of-age (Urano, 2016), until 2 months of age, KO rat’s glucose 
tolerance and GSIS were indistinguishable from WT rats (Figure 9g-h). After 
that, Wfs1 KO rats began to show increasing glucose intolerance, decreased 
basal insulin levels, and diminished glucose stimulated insulin secretion, 
culminating in diabetes with basal blood glucose levels around 20 mM at 13 
months of age (Figure 9). Therefore, Wfs1 KO rats are the first WS animal 
model with overt diabetes (Plaas et al., 2017). 
Before the strong increase in basal blood glucose levels, KO rats exhibited 
glycosuria already at 10 months of age (Figure 9c). This coincides with the 
changes in bodyweight (Figure 9a), as KO rat’s bodyweight was indistin-
guishable from WT until 3 months of age, remained slightly lower than WT 
after that, and started to decrease around the same time as their urine glucose 
levels increased (Plaas et al., 2017). 
As glucose intolerance may also result from decreased tissue responsiveness 
to insulin, 3- and 11-month-old WT and Wfs1 KO rats were subjected to insulin 
tolerance tests (Figure 9e-f). As with mouse models, there were no differences 
between WT and KO rats, regardless of age (Plaas et al., 2017). 
Figure 9. Development of diabetes mellitus in Wfs1 KO rats. (a) Wfs1 KO animals 
are slightly lighter than wild-type (WT) rats of similar ages and begin to lose weight 
after 10 months of age. (b) Basal blood glucose levels were similar for both genotypes 
up to 11 months of age; thereafter, Wfs1 KO rats develop hyperglycemia. (c) Wfs1 KO 
rats developed glycosuria after 10 months of age. (d) Insulin levels were lower in older 
Wfs1 KO animals compared to levels in WT animals of the same age. For the insulin 
tolerance tests (ITTs), human insulin was administered (1 U/kg, s.c.), and blood glucose 
levels were measured at the indicated time points. There were no genotype-associated 
changes in insulin sensitivity in either (e) young or (f) old animals. For intraperitoneal 
glucose tolerance tests (IPGTTs), blood glucose levels were measured after administ-
ration of glucose (2 g/kg i.p.). (g, h) Glucose tolerance was similar for both genotypes at 
1 and 2 months. (i) At 3 months of age, Wfs1 KO rats showed a slight glucose into-
lerance compared with WT rats, which was exacerbated at (j) 6 months. (k) Area under 
the curve for IPGTT results at different ages. (l) Glucose-stimulated increases in blood 
insulin levels (relative to baseline) 30 minutes after glucose administration, Wfs1 KO 
animals showed a defect in insulin secretion after 3 months of age. The data were 
compared using two-way ANOVAs followed by unequal N HSD post hoc tests; #p < 
0.05, ## < 0.01 between genotypes, *p < 0.05 **, p < 0.01 within genotype (vs baseline 
and vs 3 months age). The data are presented as the mean ± SEM, n = 6–8. Plaas et al., 
2017, modified by Toots. 
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4.2.2.2. Langerhans islet mass 
Wfs1 KO rats exhibited a decrease in glucose tolerance and insulin secretion, 
but no changes in insulin sensitivity. As previous reports have shown decreased 
beta cell mass in Wfs1 mouse models (Ishihara et al., 2004; Riggs et al., 2005), 
we quantified Langerhans islet size and mass from WT and KO rats at different 
ages (Plaas et al., 2017).  
At 3 months of age, Wfs1 KO and WT rats had similar islet mass, even 
though the number of small islets in WT rats was higher (Figure 10a, d). By 
7 months of age, WT rat’s islet mass had increased, but KO rats had started to 
lose islet mass, resulting in KO animals only having about half of the islet mass 
of WT rats (Figure 10b, e). This explains the KO rat’s strong glucose into-
lerance and deficit in insulin secretion at that age. By 14 months of age, Langer-
hans islets had virtually disappeared in KO rats (Figure 10c, f), verifying the 
loss of islet mass to be, at least for most part, the cause of diabetes mellitus in 
Wfs1 KO rats (Plaas et al., 2017). 
 
Figure 10. Langerhans islet mass in Wfs1 KO rats. Size distribution of islets of 
Langerhans in rats at (a) 3, (b) 7 and (c) 14 months of age. Islet mass in rats at (d) 3, (e) 
7 and (f) 14 months of age. The data were compared using one-way ANOVAs followed 
by unequal N HSD post hoc tests; *p < 0.05, ** < 0.01 between genotypes. The data are 
presented as the mean ± SEM, n = 2–6. Plaas et al., 2017, modified by Toots. 
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4.2.2.3. ER stress markers in Langerhans islets 
WFS1 function has been associated with regulating ER stress, as cells lacking 
functional WFS1 and Langerhans islets isolated from Wfs1 deficient mice both 
exhibit enhanced ER stress response (Yamada et al., 2006). Therefore, the loss 
in islet mass might be due to increased ER stress. The mRNA expressions of ER 
stress markers Xbp1 splicing and BiP were evaluated in isolated Langerhans 
islets. While there were no differences between KO and WT rat’s BiP levels 
either at 3 or 7 months of age (Figure 11m, o), Xbp1 splicing was increased 
already in 3-month-old KO rat’s islets when compared to WT (Figure 11n), and 
this difference was further exuberated by 7 months of age (Figure 11p) (Plaas et 
al., 2017). 
Quantification of BiP and XBP1 from histological slices did not reveal 
increased ER stress in KO animal’s islets at 3 months of age (Figure 11i-j), but 
showed strong increase in levels of both ER stress markers in 7-month-old KO 
rat’s Langerhans islets, compared to WT islets (Figure 11k-l) (Plaas et al., 2017). 
These results indicate that ER stress may have a critical role in Wfs1 KO rat’s 
loss of Langerhans islet mass and resulting diabetes mellitus (Plaas et al., 2017). 
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Figure 11. Expression of XBP1 and BiP in islet of Langerhans. Immunofluorescence 
analysis of endoplasmic reticulum (ER) stress markers (a, e, c, g) BiP and (b, f, d, h) 
XBP1 in islets of Langerhans (dotted lines) from 3- and 7-month-old rats. At 3 months, 
the expression of (a) BiP and (b) XBP1 in control rats and (e, f) Wfs1 KO rats was 
comparable. By 7 months, the expression of (c) BiP and (d) XBP1 remained at basal 
level in WT rats, whereas the expression of these ER stress markers was clearly 
elevated in (g, h) the islets of Langerhans of Wfs1 KO rats. (i – l) Quantification of 
signal intensity of ER stress markers. Levels of (k) BiP and (l) XBP1 were increased in 
islets of Langerhans from 7-month-old Wfs1 KO rats. (m, n, o, p) mRNA analysis of 
ER stress markers BiP and spliced Xbp1 in lysates of isolated islets of Langerhans. 
Expression level of BiP was not altered in (m) 3-month-old or (o) 7-month-old Wfs1 
KO rats compared to expression in wild-type rats. Xbp1 splicing was increased in (n) 3-
month- and (p) 7-month-old Wfs1 KO rats compared to expression in WT rats. The data 
were compared using one-way ANOVAs followed by unequal N HSD post hoc tests; 
*** p < 0.001, ** p < 0.01, * p < 0.05 between genotypes. The data are presented as the 
mean ± SEM, n = 4 to 9. Cell nuclei (blue) were counterstained with DAPI. Scalebar: 
100 µm. Plaas et al., 2017, modified by Toots. 
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Figure 12. Development of metabolic 
symptoms in Wfs1 KO rat. Toots et 
al., 2018 (2), modified by Toots. 
4.2.2.4. Conclusion 
Rat model of Wolfram syndrome exhibits clear progression of diabetic 
symptoms (Figure 12) with normal Langerhans islet mass, insulin secretion and 
glucose tolerance at early age. In time, their insulin secretion decreases due to 
loss in beta cell mass (as indicated by reduction in Langerhans islet mass), most 
likely as a result from ER stress. This leads to glucose intolerance that 
culminates with diabetes mellitus, basal hyperglycemia and glycosuria (Plaas et 
al., 2017). 
With the progression of symptoms, Wfs1 KO rat presents a new model to 
evaluate the effectiveness of drugs to possibly slow the progression of both 
Wolfram syndrome, and diabetes mellitus resulting from loss of beta cells due 
to ER stress (Plaas et al., 2017). 
40 
4.3. Treatment of Wfs1 deficient rats with liraglutide 
(Paper III) 
4.3.1. Liraglutide effect on glucose intolerant Wfs1 KO rats 
GLP-1 regulates directly through GLP-1R and indirectly through neuronal and 
endocrine pathways different physiological processes (Bockaert & Pin, 1999). 
The precise ways, GLP-1 affects cells, are still being identified. Among other 
things, GLP-1 increases insulin secretion in glucose dependent manner, regu-
lates cell apoptosis, proliferation, and decreases ER stress (Bouskine et al., 
2009; Persaud, 2017; Sargsyan et al., 2016; Wang et al., 2004). Acute treatment 
with GLP-1 receptor agonist exenatide has shown blood glucose lowering effect 
in Wfs1 KO mice (Sedman et al., 2016). To see if a similar effect can be seen in 
Wfs1 KO rats, 5-month-old Wfs1 KO and WT rats were subjected to glucose 
tolerance test before, and after 8 days of chronic liraglutide (GLP-1 receptor 
agonist) treatment, with last injection 4.5 hours before the experiment (Toots et 
al., 2018 (2)). 
As expected, unlike WT rats, 5-month-old naïve Wfs1 KO rats exhibited 
long-lasting hyperglycemia, in response to glucose (p<0.001) (Figure 13a, b).  
8-day treatment with liraglutide was able to normalize glucose tolerance in KO 
rats, decreasing area-under-curve to similar level with WT rats (Figure 13b) 
(Toots et al., 2018 (2)). 
Serum insulin and C-peptide levels were significantly lower in KO rats than 
in WT rats, measured 30 minutes after glucose challenge (Figure 13c-d). There 
was no statistical difference in Wfs1 KO rats 30 min after glucose injection 
insulin or C-peptide levels before and after liraglutide treatment. However, 
liraglutide treatment decreased basal levels of both peptides. Taken this into 
consideration, KO rats had no increase in response to glucose before treatment, 
but after liraglutide treatment, their 30 min post glucose levels were two times 
higher than basal levels. Even though there was no statistical change in 
secretion before and after treatment, this change compared to baseline level 
indicates improved insulin secretion. Therefore, short-term treatment with GLP-
1 agonist liraglutide normalizes glucose tolerance in Wfs1 KO rats, most likely 
by increasing GSIS (Toots et al., 2018 (2)). 
41 
 
Figure 13. Repeated liraglutide effect on glucose intolerant 5-month-old Wfs1 KO 
rats. (a) IPGTT (2g/kg) before and after 8-day chronic administration of 0.4 mg/kg 
liraglutide to 5-month-old male Wfs1 KO and control rats. (b) Decrease in IPGTT 
(2g/kg) Area under curve before and after chronic liraglutide treatment for 8 days. 
Glucose-stimulated increases in blood (c) insulin and (d) C-peptide levels before and 30 
minutes after glucose administration. The data were compared using repeated measures 
ANOVA followed by unequal N HSD post hoc tests; £££ p<0.001 compared to WT 
AUC during same IPGTT. *** p<0.001 compared to baseline of the same genotype 
during the same IPGTT. ## p<0.01 compared to WT animals in the same timepoint 
during the same IPGTT. ¤ p<0.05 compared to WT saline animals in the same timepoint 
during the first IPGTT. The data are presented as the mean ± SEM, n=6–8. Toots et al., 
2018 (2), modified by Toots. 
 
  
4.3.2. Preventive treatment with liraglutide 
Previous experiments showed that Wfs1 KO rats exhibit increased ER stress in 
Langerhans islets, which may also be the cause for the decrease in islet mass 
and development of glucose intolerance in KO rats. GLP-1 agonist exendin-4 
has been shown to reduce ER stress in cardiac myocytes (Younce et al., 2013), 
and GLP-1 receptor agonist liraglutide has been shown to decrease beta cell 
apoptosis in pre-diabetic Goto-Kakizaki rats (Luo et al., 2013). As short-term 
chronic treatment is able to restore glucose tolerance and insulin secretion in  
5-month-old Wfs1 rats, we aimed to see, if starting pretreatment with liraglutide 
before the onset of symptoms, could decrease the ER stress and possibly 
apoptosis of beta cells, and therefore, postpone or protect against development 
of glucose intolerance in Wfs1 KO rats (Toots et al., 2018 (2)). 
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4.3.2.1. Glucose tolerance 
We started the experiment with 2-month-old KO rats, whose blood glucose 
profile after glucose challenge was indistinguishable from WT littermates 
(Figure 14b). During the 19-week long experiment, the glucose tolerance profile 
of Wfs1 KO rats receiving liraglutide remained similar to that of their WT 
littermates, while Wfs1 KO rats in control group developed glucose intolerance 
(Figure 14b-e), also demonstrated by stable increase of area-under-curve 
(p<0.001) (Figure 14f). One week before the last IPGTT, rats’ insulin sensitivity 
was also tested, revealing no differences between genotypes or treatment-
groups (Figure 14i) (Toots et al., 2018 (2)).  
 
 
4.3.2.2. Langerhans islet mass 
As shown before, KO rats receiving saline injections had almost two-fold lower 
Langerhans islet mass than WT rats in saline group (p<0.01) (Figure 14g). 
Similarly to previous reports, liraglutide decreased islet mass in WT rats (Figure 
14g) (Ellenbroek et al., 2013; Mondragon et al., 2014). However, liraglutide 
seemed to have the opposite effect in Wfs1 KO rats, most likely by inhibiting 
decrease in beta cell mass seen in previous experiments (Figure 14g) (Toots et 
al., 2018 (2)). 
Liraglutide treatment is accompanied by decrease in body weight (Figure 
14a). Taking this into account, Langerhans islet mass/body weight ratio was 
unchanged upon liraglutide treatment in WT rats. However, saline-treated Wfs1 
KO rats had significantly lower Langerhans islet mass/body mass ratio (p<0.05) 
than saline-treated WT rats and this difference was eliminated under liraglutide 
treatment, bringing Wfs1 KO rats’ Langerhans islet mass/body mass ratio 
similar to that of WT rats (Figure 14h) (Toots et al., 2018 (2)). 
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 Figure 14. Development of glucose intolerance over 19 weeks of liraglutide 
treatment. (a) Weight change over 19 weeks of liraglutide administration. Blood 
glucose profile after glucose challenge during liraglutide treatment (b) before, (c) 7 
weeks, (d) 14 weeks and (e) 19 weeks after the beginning of liraglutide treatment. 
(f) Area under curve analyses for IPGTT results at different timepoints. (g) Langerhans 
islet mass and (h) Langerhans islet mass/body weight ratio after 19 weeks of liraglutide 
treatment. (i) Insulin tolerance test with 1U/kg human insulin after 18 weeks of 
liraglutide treatment. The data were compared using repeated measures ANOVA or one-
way ANOVA followed by unequal N HSD post hoc tests; * p<0.05, ** p<0.01, 
*** p<0.001 compared to (same-age) WT saline-treated animals. ### p<0.001 
compared to same-age Wfs1 KO liraglutide-treated animals. The data are presented as 
the mean ± SEM, n=12–15 (weight and IPGTT), n=6–8 (ITT), n=4–6 (islet 
measurements). Toots et al., 2018 (2), modified by Toots. 
 
4.3.2.3. Insulin, C-peptide and glucagon secretion 
During 19 weeks, we saw no change is insulin or C-peptide concentration, 
measured 30 minutes after glucose injection (Figure 15a-e). However, liraglutide 
decreased basal insulin and C-peptide levels (Figure 15d-e). When compared to 
basal levels, liraglutide-treated Wfs1 KO rats showed a twofold increase in both 
insulin and C-peptide levels 30 minutes after stimulation, while saline-treated 
Wfs1 KO rats’ insulin and C-peptide levels did not change from the basal level 
in response to glucose. While insulin is rapidly removed from circulation by the 
liver, the half-life of C-peptide is at least 20 minutes (Canas et al., 1995; Katz & 
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44 
Rubenstein, 1973). Therefore, we can presume that C-peptide concentration 
measured 30 minutes after glucose challenge reflects the combined secretion of 
first- and second-phase insulin during the whole stimulatory period. These 
results indicate constant low-level insulin secretion from Wfs1 KO rats that is 
only slightly elevated by glucose challenge. Liraglutide treatment appears to 
correct that deficit by enhancing the first phase of insulin secretion. In addition 
to enhancement in insulin secretion, GLP-1R agonists have also been shown to 
reduce pro-insulin:insulin ratio (this ratio is elevated in subjects with type 2 
diabetes), possibly as a result of reduced ER stress and therefore, improved 
proinsulin processing (Degn et al., 2004). Increased pro-insulin:insulin ratio has 
also been shown in mice lacking functional WFS1 (Noormets et al., 2011). 
Improper pro-insulin processing may also explain the lack of blood glucose 
lowering effect of depolarizing medication in Wfs1 deficient mice (Sedman et 
al., 2016). As both insulin and C-peptide ELISAs used in current study may 
also cross-react with pro-insulin (according to our inquiry to the manufacturer), 
the improved glycemic control may also in part result from properly processed 
insulin after liraglutide treatment. These results are in accordance with those 
obtained from Wfs1 deficient mice, whose blood glucose levels during IPGTT 
are significantly lowered after treatment with the GLP-1 analogue exenatide, an 
effect not accompanied by increased serum insulin concentration 30 minutes 
after stimulation (Sedman et al., 2016). Similar results were recently also 
obtained on one of the Wfs1 deficient mouse models, whose blood glucose 
control and insulin secretion were improved following both acute and chronic 
treatment with GLP-1R agonist exenatide. However, they did not see changes in 
pancreatic islet mass, most likely due to shorter treatment protocol (4 weeks) 
(Kondo et al., 2018). Also, administration of exenatide to Wolfram syndrome 2 
(WS2, CISD2 mutation) patient lowered daily insulin dose 70% and improved 
glycemic control (Danielpur et al., 2016). Knock-down of CISD2 by shRNA in 
INS-1 cells decreased insulin secretion in response to glucose or KCl by 30% 
and this effect was also reversed by exenatide treatment (Danielpur et al., 2016). 
The similar response in these WS and WS2 models indicates the effectiveness 
of GLP-1 analogues, probably resulting from the same molecular mechanism 
(Toots et al., 2018 (2)).  
Glucagon levels in liraglutide treated Wfs1 KO rats were significantly lower 
than in saline treated rats (p<0.05) (Figure 15f). The change in first-phase 
insulin secretion may also be at least partially responsible for the change in 
glucagon secretion, as intra-islet insulin, secreted from beta cells, is necessary 
for glucagon secretion inhibition (Greenbaum et al., 1991; Starke et al., 1987; 
Xu et al., 2006). Also, both liraglutide and GLP-1 have been shown to decrease 
glucagon levels (Harder et al., 2004; Zander et al., 2002). Exenatide experi-
ments with Wfs1 KO mice did not reveal any differences in glucagon secretion, 
but this might be due to a shorter treatment protocol or the fact that Wfs1 KO 
mice do not exhibit such strong progression of glucose intolerance over time 
(Sedman et al., 2016). Disturbances in suppression of mealtime glucagon con-
centration are also present in type 2 diabetes patients, whose hepatic glucose 
production contributes to hyperglycemia (Bagger et al., 2014; Junker et al., 
45 
2016). Changes in both insulin (as indicated by C-peptide levels) and glucagon 
secretion in Wfs1 KO rats are corrected by liraglutide treatment, indicating 
improved beta and alpha cell sensitivity and function (Toots et al., 2018 (2)).  
 
 
Figure 15. Serum insulin, C-peptide, and glucagon levels before and 30 minutes 
after glucose administration. (a-d) Insulin levels after various time on liraglutide 
treatment, (e) C-peptide and (f) glucagon levels after 19 weeks on liraglutide treatment. 
The data were compared using repeated measures ANOVA followed by unequal 
N HSD post hoc tests; * p <0.05, ** p<0.01, *** p<0.001 compared to the baseline of 
the same animals; # p <0.05, ## p<0.01, ### p<0.001 compared to WT animals of same 
treatment at the same timepoint; ¤ p <0.05, ¤¤¤ p<0.001 compared to Saline treatment 
of the same GT at the same timepoint. The data are presented as the mean ± SEM, 
n=12–15. Toots et al., 2018 (2), modified by Toots. 
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46 
4.3.2.4. Gene expression analyses from Langerhans islets 
Improvement in Langerhans islet mass and hormone secretion indicates overall 
better health of Langerhans islets. To assess the health of islet cells and ER 
stress in islets, we performed gene expression analyses from Langerhans islets, 
isolated from rats after 19 weeks on saline or liraglutide treatment (Toots et al., 
2018 (2)). 
Analyses revealed no significant changes in Wfs1 expression (Figure 16a). 
However, GLP-1 receptor expression in Langerhans islets was decreased by 
30% in Wfs1 KO animals, compared to WT (p<0.001). Downregulation of 
GLP-1 receptor in beta cells has also been observed in diabetic patients and 
animal models of diabetes (Shu et al., 2009; G. Xu et al., 2007). Chronic 
treatment with liraglutide had a slight increasing effect on GLP-1 receptor 
mRNA levels in both genotypes (Figure 16b) (Toots et al., 2018). 
In saline treated group, KO rats had a higher proliferation marker Ki67 
expression than WT rats (p<0.05) (Figure 16f). Even though decline in 
Langerhans islet mass did not occur in liraglutide-treated Wfs1 KO rats, 
Langerhans islet cell proliferation had significantly declined in both genotypes 
(p<0.05), indicating that the main effect in improved Langerhans islet mass was 
not caused by increased proliferation in Wfs1 KO rats. These results are in 
accordance with those obtained from pre-diabetic Goto-Kakizaki rats, whose 
proliferation marker Ki67 levels had also declined in response to liraglutide 
treatment (Luo et al., 2013). In humans, beta cell proliferation is very low after 
the first few years of life, and treatments increasing proliferation in rodents are 
unlikely to cause the same in human beta cells (Wang et al., 2015). Therefore, 
as liraglutide’s positive effect appears not to be caused by increased 
proliferation, it remains a promising treatment strategy for human WS patients 
(Toots et al., 2018 (2)). 
Unlike Luo et al, we did not see a significant effect of liraglutide on islet 
apoptosis (Figures 16g-k) (Luo et al., 2013). This might be due to the fact that 
Luo et al. used very young rats, whose beta cells are actively proliferating and a 
shorter treatment protocol (Finegood et al., 1995; Luo et al., 2013). Also, 
reduction in beta cell mass develops very slowly over time, as fasting 
hyperglycemia is apparent around 13 months of age, and even then, most likely 
there is some small portion of beta cells left (Plaas et al., 2017). Moreover, we 
are analyzing whole islets, making it more difficult to detect differences only 
apparent in beta cells. In healthy rats, 20–35% islet cells are not beta cells and 
this ratio is even higher in aging Wfs1 KO rats (Kageyama et al., 2005), who 
lose beta cell mass. Therefore, it is possible that the difference in rate of 
apoptosis is so low, that we are not able to detect it (Toots et al., 2018 (2)). 
The ER stress markers Grp78 and Xbp1 splicing were increased in Wfs1 KO 
rats compared to WT littermates. Liraglutide treatment decreased ER stress, 
regardless of genotype, resulting in similar levels in saline-treated WT and 
liraglutide-treated KO animals (p<0.05) (Figure 16c–d).  
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Figure 16. Langerhans islet gene expression analyses after 19 weeks of liraglutide 
treatment compared to WT saline group. Gene expression of (a) Wolframin1; 
(b) GLP-1 receptor; ER stress markers (c) Grp78 and (d) Xbp1 splicing; inflammation 
marker (e) IP10; proliferation marker (f) Ki67; apoptosis markers (g) Atf4, (h) Bax, 
(i) Caspase 1, (j) Caspase 3, and (k) Bcl2. The data were compared using factorial 
ANOVA followed by unequal N HSD post hoc tests; * p<0.05, ** p<0.01, *** p<0.001 
compared to WT animals of the same treatment; # p<0.05, ## p<0.01 compared to 
saline animals of the same GT. The data are presented as the mean ± SEM, n=4–8. 
Toots et al., 2018 (2), modified by Toots. 
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48 
Inflammatory marker IP10 levels revealed no differences between genotypes, in 
neither saline nor liraglutide treatment group. However, liraglutide treatment 
had a significant decreasing effect on IP10 expression in both genotypes 
(p<0.05) (Figure 16e). Inflammation has long been recognized as a contributing 
factor in the development of diabetes (Ehses et al., 2007; McDaniel et al., 
1996), and both GLP-1 agonists and DPP-4 inhibitors have been shown to sup-
press inflammation in pancreatic islets and adipose tissue (Dobrian et al., 2011; 
Huang et al., 2015; Velmurugan et al., 2012). Taken together, these results 
indicate better overall health of islet cells (Toots et al., 2018 (2)). 
 
 
4.3.3. Conclusion 
Early chronic intervention with GLP-1 receptor agonist liraglutide decreased the 
loss of Langerhans islet mass in Wfs1 mutant rats, improved insulin and 
glucagon secretion control, and reduced ER stress and inflammation in 
Langerhans islets. Thus, treatment with GLP-1 receptor agonists is a promising 
strategy as a preventive treatment for human WS patients (Toots et al., 2018 
(2)). 
 
 
4.4. Feasibility of WS rat model 
Currently existing Wfs1 deficient mouse models develop glucose intolerance at 
an early age, exhibit reduced insulin secretion, and reduction in beta cell mass. 
However, while human patients with WS develop insulin dependent diabetes at 
average age of six years, current mouse models seem to not exhibit overt 
diabetes (except for few occasional animals in different genetic backgrounds) 
(Ishihara et al., 2004; Riggs et al., 2005; Urano, 2016). 
Wfs1 KO rat is the first WS animal model to show clear signs of progressing 
diabetic symptoms due to increased ER stress, leading to decrease in beta cell 
mass, culminating in overt diabetes. While human patients develop diabetes 
around 6-years-of-age, Wfs1 rats develop diabetes already around 1 year. This 
might be due to very fast metabolism of rats or, due to Sprague-Dawley male 
rats very fast gain of bodyweight, putting more strain on beta cells. Our 
preliminary experiments have shown that female Wfs1 KO rats develop 
diabetes later than male rats, possibly because of much slower weight gain or 
hormonal differences. 
Wfs1 KO rats show increased glucagon secretion and reduced GLP-1R 
mRNA expression on islet cells. Both of these symptoms are also characteristic 
for type 2 diabetes patients (Bagger et al., 2014; Shu et al., 2009; Xu et al., 
2007). As progression of diabetes in Wfs1 KO rats is slow and accompanied by 
symptoms present in type 2 diabetes, Wfs1 rat model can not only be used to 
study WS, but also presents a great model to test new diabetes drugs. 
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4.5. Future directions 
Future experiments will most likely be performed using the new rat model, as 
rat offers much better model for long-term experiments (e.g. for repeated blood 
collection, more precise in vivo imaging). In current work, we started the 
experiment with 2-month-old rats and ended the experiment when strong 
hyperglycemia in response to glucose in Wfs1 KO saline group had developed. 
In future, it would be advised to perform lifelong experiments, starting few 
weeks after birth. This would also require bigger experimental groups, to 
analyze animals at different time-points. There are also newer GLP-1R agonists 
that would not require everyday injections and would reduce the stress to the 
animals. 
WS consists of several different symptoms. In current work, only the first 
symptom – diabetes, was studied. GLP-1R agonists have also been shown to 
have neuroprotective properties, therefore, in next experiments, the effect of 
these medications to other symptoms of WS should be assessed. 
Currently, patients reach the diagnosis of WS only after several symptoms 
have developed and the medical treatment is limited to managing the symptoms. 
As genetic testing is getting more and more available, in the future, it might be 
possible for children to get tested for WFS1 mutations soon after birth. Pretreat-
ment before the onset of symptoms might then provide these patients with the 
possibility to postpone the development of symptoms and to increase the 
amount of high quality years and increase life expectancy. 
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CONCLUSIONS 
1.  Wfs1 deficiency causes glucose intolerance in mice as a result of decreased 
insulin secretion. To a lesser extent, this deficit is also apparent in hetero-
zygous Wfs1 deficient mice, even though they do not exhibit glucose into-
lerance. Activation of M3 receptors on beta cell by carbachol was able to 
initiate insulin secretion from beta cells and normalize blood glucose control 
in Wfs1 deficient mice. Therefore, selective M3R agonists and possibly 
other ligands, able to activate the same pathways in beta cell, are a promising 
way to release insulin and to reverse glucose intolerance, resulting from 
Wfs1 deficiency. 
2. Using zinc-finger technology, three different Wfs1 mutant rat lines with 
mutations in exon 5 were created. Genomic sequencing revealed that two of 
the lines (Wfs1-ex5-KO232 and Wfs1-ex5-KO266) had an in frame deletion 
in exon 5 of the Wfs1 gene and the third line (Wfs1-ex5-INS244) had an in 
frame substitution in exon 5 of the Wfs1 gene. This substitution is predicted 
to result in amino-acids 224–226 (LQK) being substituted with YCMNTI in 
the WFS1 protein. All three rat lines exhibited glucose intolerance at 7 months 
of age, only line Wfs1-ex5-KO232 (in experiments marked as Wfs1 KO) 
males were used in subsequent experiments. 
Rat model of Wolfram syndrome exhibits normal Langerhans islet mass, 
insulin secretion and glucose tolerance at an early age. In time, their insulin 
secretion decreases due to loss in beta cell mass (as indicated by reduction in 
Langerhans islet mass) as a result from ER stress. This leads to glucose 
intolerance that culminates with diabetes mellitus, basal hyperglycemia and 
glycosuria. With progression of symptoms, Wfs1 KO rat presents a new 
model to evaluate the effectiveness of drugs to possibly slow the progression 
of both Wolfram syndrome, and diabetes mellitus resulting from loss of beta 
cells due to ER stress. 
3.  Treatment with GLP-1R agonist liraglutide was started at 2 months of age, 
when Wfs1 KO rat’s glucose tolerance is indistinguishable from WT rats. 
Early chronic intervention decreased the loss of Langerhans islet mass in 
Wfs1 mutant rats, improved insulin and glucagon secretion control, and 
reduced ER stress and inflammation in Langerhans islets. Thus, treatment 
with GLP-1 receptor agonists is a promising strategy as a preventive treat-
ment for human WS patients. 
4.  Similarly to human patients, Wfs1 KO rat is the first rodent model of WS to 
develop overt diabetes with basal hyperglycemia. With normal glucose 
homeostasis at an early age, Wfs1 KO rats show progressing diabetic 
symptoms due to increased ER stress, leading to decrease in beta cell mass, 
culminating in overt diabetes.  
Similarly to patients with type 2 diabetes, Wfs1 KO rats show increased 
glucagon secretion and reduced GLP-1R mRNA expression in islet cells. 
With these typical type 2 diabetes symptoms and slow progression of 
diabetes in Wfs1 KO rats, Wfs1 rat model can not only be used to study WS, 
but also presents a great model to test new diabetes drugs.  
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SUMMARY IN ESTONIAN 
Farmakoloogiline väljakutse diabeedi fenotüübi arengu  
pidurdamiseks Wolframi sündroomi näriliste mudelites 
Wolframi sündroom (WS) on autosomaalne retsessiivne haigus, mida põhjus-
tavad mutatsioonid Wolframin1 (WFS1) geenis. Esimese sümptomina avaldub 
patsientidel progresseeruvast beeta rakkude hävinemisest põhjustatud suhkru-
diabeet. Suure tõenäosusega põhjustab rakkude hävinemist häiritud rakusisene 
Ca2+ taseme regulatsioon, mis viib suurenenud endoplasmaatilise retiikulumi 
stressi ning rakusurmani. Suhkrudiabeedile järgneb enamasti optilise närvi 
atroofiast põhjustatud nägemise halvenemine. Sensorineuraalne kurtus, mage-
diabeet, kuseteede probleemid ja neuroloogilised probleemid järgnevad erineva 
sageduse ning raskusastmetega. WS-ga kaasneb erinevaid neuroloogilisi prob-
leeme nagu neuropaatia, peavalud, ataksia, düsfaagia ning ajutüve atroofia. 
Lisaks kannatavad paljud patsiendid psühhiaatriliste probleemide all. Ajutüve 
atroofiast põhjustatud hingamisseiskus on WS patsientide peamiseks surma 
põhjuseks kolmekümnendates eluaastates.  
Kui WS sagedus erinevates riikides on hinnanguliselt 1:100 000-1:770 000, 
siis heterosügootsete WFS1 mutatsiooni kandjate sagedus on umbkaudu 1:100-
1:354. Lisaks haruldastele WFS1 mutatsioonidele, mis põhjustavad dominantset 
autosomaalset diabeeti, on ülegenoomsed assotsatsiooni uuringud leidnud, et 
heterosügootsetel WFS1 mutatsiooni kandjatel on suurenenud risk teist tüüpi 
diabeedi tekkeks. Teist tüüpi diabeet on aina laiemini leviv globaalne tervise-
probleem, hõlmates ligi 90% diabeedi juhtudest. Teist tüüpi diabeet on põhjus-
tatud elustiili valikute ning geneetiliste riskide koostoimest, viies vähenenud 
insuliini tundlikkuse ning sekretsioonini. Seega aitaks parem arusaam WFS1 
funktsioonist mitte ainult haruldast WS põdevaid patsiente, vaid ka inimesi, kes 
kannatavad selliste laialt levinud haiguste nagu teist tüüpi diabeet käes. 
Hetkel ei ole olemas ravimeid, mis suudaksid aeglustada WS kulgu või seda 
ravida. Seetõttu on medikamentoosne ravi fokusseeritud sümptomite leevenda-
misele. Sellest tulenevalt oli käesoleva doktoritöö peamiseks eesmärgiks leida 
uusi ravi strateegiaid ning võimalikke ravimikandidaate, mis võiksid aidata 
Wolframi sündroomi patsiente. 
Esimeses artiklis uurisime Wfs1 mutatsioonist põhjustatud glükoosi talu-
matust ning insuliini sekretsiooni Wfs1 puudulikkusega hiirtes. Lisaks uurisime 
võimalusi normaliseerida insuliini sekretsiooni aktiveerides muskariini 3 retsep-
torit (M3R). Insuliini sekretsiooni mõjutavad paljud erinevad hormoonid ja 
virgatsained. Perifeerse parasümpaatilise närvisüsteemi virgatsaine atsetüül-
koliin võimendab insuliini sekretsiooni beeta rakkudest pärast seondumist M3 
retseptorile. Varasemad uuringud on näidanud, et selle mehhanismi kaudu on 
võimalik taastada insuliini sekretsioon näiteks geneetilises diabeedi mudelis, 
Goto-Kakizaki rotis. Sarnaselt varasematele katsetele leidsime, et Wfs1 puudu-
likkusega homosügootsetel hiirtel on oluliselt vähenenud glükoosi stimuleeritud 
insuliini sekretsioon, mis tingib glükoosi manustamisel hüperglükeemia. Lisaks 
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avastasime, et kuigi heterosügootsetel Wfs1 hiirtel ei esine glükoosi manusta-
mise järel hüperglükeemiat, on nendel loomadel insuliini vabanemine häiritud. 
See langeb kokku suurenenud teist tüüpi diabeedi tekke võimalusega hetero-
sügootsetel WFS1 mutatsiooniga inimestel. M3R aktiveerimine, kasutades 
karbakooli, aitas homosügootsete hiirte beeta rakkudest vabastada insuliini ning 
normaliseeris sellega nende veresuhkru taseme. Seega on selektiivsed M3 
agonistid ning teised ravimid, mis suudavad aktiveerida beeta rakkudes samu 
mehhanisme, lootustandvad vahendid Wfs1 defitsiidist põhjustatud insuliini 
sekretsiooni häirete ja glükoosi talumatuse raviks. 
Erinevalt WS patsientidest ei tekki ühelgi hetkel olemasoleval WS hiire-
mudelil märkimisväärset diabeeti oluliselt suurenenud basaalse veresuhkruga. 
Seega on nende kasutamine leidmaks uusi ravimikandidaate piiratud. Teises 
artiklis püüdsime luua ja kirjeldada uut WS mudelit, mis oleks võimeline pare-
mini jäljendama inimestel kujuneva diabeedi teket. Selle jaoks tehti tsink-
sõrmede tehnoloogiat kasutades kolm erinevat rotiliini, mutatsiooniga viiendas 
eksonis. Kolmest liinist kahel esines raaminihketa deletsioon ning ühel lühike 
raaminihketa insertsioon. Kõigil kolmel liinil oli tugev glükoosi talumatus juba 
7 kuu vanuselt. Edasistes eksperimentides kasutasime hetkel ainult ühe liini isa-
seid loomi. Uue rotimudeli põhjalikum uurimine näitas, et kuni 2 kuu vanustel 
loomadel on metsiktüüpi pesakonnakaaslastele sarnane glükoosi tolerantsus, 
insuliini sekretsioon ning Langerhansi saarekeste mass. Edasi hakkab nende 
glükoosi tolerantsus ja insuliini sekretsioon progresseeruvalt halvenema, viies 
basaalse hüperglükeemia ja glükosuuriani 13 kuu vanuselt. Halvenev insuliini 
sekretsioon oli põhjustatud vähenevast Langerhansi saarte hulgast, mis oma-
korda oli põhjustatud suurenenud endoplasmaatilise retiikulumi stressist. Seega 
on Wfs1 puuduliku roti puhul tegemist esimese WS loommudeliga, millel 
tekkib progresseeruvate sümptomite tulemusel insuliinist sõltuv diabeet. 
Kolmandas artiklis kasutasime progresseeruvate sümptomitega uut WS roti-
mudelit leidmaks uusi ravimikandidaate pidurdamaks WS sümptomite progres-
siooni. GLP-1 (glükagooni-sarnane peptiid-1) retseptori agonistid on uus palju-
tõotav klass diabeedi-vastaseid ravimeid. GLP-1 retseptori agonistid regu-
leerivad glükoosi homöostaasi, metabolismi ja neuronite elulemust nii kudedes, 
mis ekspresseerivad GLP-1 retseptoreid kui ka kaudselt läbi endokriinsete ja 
neuraalsete radade. GLP-1 agonistid vähendavad endoplasmaatilise retiikulumi 
stressi ning vähendavad beeta rakkude apoptoosi diabeedi-eelses Goto-Kakizaki 
rotis. Lisaks põhjustab akuutne ravi GLP-1 agonistiga antidiabeetilist efekti 
Wfs1 puudulikkusega hiires. Sellest tulenevalt alustasime Wfs1 puudulikkusega 
rottidel kroonilist ravi GLP-1 agonist liraglutiidiga enne haiguse sümptomite 
avaldumist, 2 kuu vanuselt. 19 nädala jooksul halvenes ravimit mitte saanud 
Wfs1 rottide glükoosi tolerantsus ja Langerhansi saarte mass oluliselt. Liraglu-
tiidiga ravitud loomade glükoosi tolerantsus jäi metsiktüüpi loomadele sarna-
seks. Liraglutiid oli võimeline pidurdama Wfs1 puudulike rottide Langerhansi 
saarekeste massi vähenemist tänu vähenenud endoplasmaatilise retiikulumi 
stressile. Lisaks parandas liraglutiid üldiselt Langerhansi saarekeste tervislikku 
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seisundit, mis väljendus vähenenud põletikumarkerite ekspressioonis ning para-
nenud insuliini ja glükagooni sekretsioonis. 
Hetkel puuduvad ravimid peatamaks WS arengut. Antud töös näitasime 
GLP-1 analoogi arvestatavat terapeutilist efekti hoidmaks ära või aeglustamaks 
WS diabeedi sümptomite kujunemist. Varajane diagnoosimine ning ravi GLP-1 
retseptori agonistidega võib osutuda paljulubavaks ravivõimaluseks inim-
meditsiinis, aidates oluliselt parendada ja pikendada WS patsientide elu.  
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